NCT00928447View on ClinicalTrials.gov

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 23, 2009

Primary Completion Date

September 13, 2009

Study Completion Date

September 13, 2009

Conditions
Dermatitis, Allergic Contact
Interventions
DRUG

rHuPH20

0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20

DRUG

Placebo

0.25 mL ID syringe push bolus injection of placebo control

Trial Locations (1)

46360

Symbio Phase I Unit, Saint Anthony Memorial Research Center, Michigan City

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT00928447 - Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis | Biotech Hunter | Biotech Hunter